Blocking IL-17a Signaling Decreases Lung Inflammation and Improves Alveolarization in Experimental Bronchopulmonary Dysplasia
- 6 August 2024
- journal article
- research article
- Published by Elsevier in The American Journal of Pathology
- Vol. 194 (11) , 2023-2035
Abstract
No abstract availableKeywords
This publication has 45 references indexed in Scilit:
- IL-17A induces valvular endothelial inflammation and aggravates calcific aortic valve diseaseBiochemical and Biophysical Research Communications, 2023
- Dynamic Changes of NCR− Type 3 Innate Lymphoid Cells and Their Role in Mice with Bronchopulmonary DysplasiaInflammation, 2022
- Effects of early vitamin D supplementation on the prevention of bronchopulmonary dysplasia in preterm infantsPediatric Pulmonology, 2022
- IL-17 stimulates neutrophils to release S100A8/A9 to promote lung epithelial cell apoptosis in Mycoplasma pneumoniae–induced pneumonia in childrenBiomedicine & Pharmacotherapy, 2021
- Salivary cytokine - A non-invasive predictor for bronchopulmonary dysplasia in premature neonatesCytokine, 2021
- Sensitivity analyses for average treatment effects when outcome is censored by death in instrumental variable modelsStatistics in Medicine, 2019
- IL-17A suppresses and curcumin up-regulates Akt expression upon bleomycin exposureMolecular Biology Reports, 2018
- Chorioamnionitis and subsequent bronchopulmonary dysplasia in very-low-birth weight infants: a 25-year cohortJournal of Perinatology, 2016
- Thymic Selection Determines γδ T Cell Effector Fate: Antigen-Naive Cells Make Interleukin-17 and Antigen-Experienced Cells Make Interferon γImmunity, 2008
- Interleukin 17–producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineagesNature Immunology, 2005